Live News EARNINGS ARTICLE M impact Sep 28, 2026, 11:50 AM UTC

Redcare Pharmacy raises 2026 revenue guidance again on strong Germany Rx momentum

Company now expects 2026 total revenue growth of 16% to 18%, from 15% to 17%. Germany Rx revenue now seen at a higher range, with adjusted EBITDA margin unchanged at 2.5% to 3.0%.

RDC.DE

SquawkNews Newsroom 1 updates Updated Sep 28, 2026, 11:50 AM UTC

Story updates

11:50:58 AM UTC

SquawkNews

Redcare Pharmacy lifted full-year 2026 revenue guidance for a second time, citing sustained prescription-drug momentum in Germany. Total revenue growth now seen at 16% to 18%, up from 15% to 17%; non-Rx growth maintained at 10% to 12%. Germany Rx revenue forecast raised to EUR 730-760 million, implying 45% to 51% growth versus EUR 680-720 million previously. Adjusted EBITDA margin outlook kept at 2.5% to 3.0%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redcare Pharmacy NV published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2406332_en) on September 28, 2026, and is solely responsible for the information contained therein. (C)

V. / Key word(s): Forecast / Full year Redcare Pharmacy raises again full-year 2026 revenue guidance driven by strong Rx momentum in Germany 28-Sep-2026 / 13:48 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by 1 EQS News — a service of 2 EQS Group. The issuer is solely responsible for the content of this announcement.

══════════════════════════════════════════════════════════════════════════ Redcare Pharmacy raises again full-year 2026 revenue guidance driven by strong Rx momentum in Germany Sevenum, the Netherlands, September 28, 2026. V. announces that it is raising its full-year 2026 guidance for the second time this year, driven by continued strong Rx revenue momentum in Germany. 0% (unchanged) Contact: Irina Zhurba Investor Relations Redcare Pharmacy End of Inside Information ══════════════════════════════════════════════════════════════════════════ 28-Sep-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

V. com Internet: ISIN: NL0012044747, DE000A19Y072 WKN: A2AR94, A19Y072 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX LEI Code: 529900JK6UXHY1YKZ082 EQS News ID: 2406332 End of Announcement EQS News Service 2406332 28-Sep-2026 CET/CEST References Visible links 1. 2. 3.